The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy.
Abstract
PURPOSE: To determine the efficacy and toxicity of a high-dose interleukin-2 (IL-2) regimen in patients with metastatic renal cell carcinoma. PATIENTS AND METHODS: Two hundred fifty-five assessable patients were entered onto seven phase II clinical trials. Proleukin (aldesleukin; Chiron Corp, Emeryville, CA) 600,000 or 720,000 IU/kg was administered by 15-minute intravenous (i.v.) infusion every 8 hours for up to 14 consecutive doses over 5 days as clinically tolerated with maximum support, including pressors. A second identical cycle of treatment was scheduled following 5 to 9 days of rest, and courses could be repeated every 6 to 12 weeks in stable or responding patients. RESULTS: The overall objective response rate was 14% (90% confidence interval [CI], 10% to 19%), with 12 (5%) complete responses (CRs) and 24 (9%) partial responses (PRs). Responses occurred in all sites of disease, including bone, intact primary tumors, and visceral metastases, and in patients with large tumor burdens or bulky individual lesions. The median response duration for patients who achieved a CR has not been reached, but was 19.0 months for those who achieved a PR. Baseline Eastern Cooperative Oncology Group (ECOG) performance status (PS) was the only predictive prognostic factor for response to IL-2. While treatment was associated with severe acute toxicities, these generally reversed rapidly after therapy was completed. However, 4% of patients died of adverse events judged to be possibly or probably treatment-related. CONCLUSION: High-dose IL-2 appears to benefit some patients with metastatic renal cell carcinoma by producing durable CRs or PRs. Despite severe acute treatment-associated toxicities, IL-2 should be considered for initial therapy of patients with appropriately selected metastatic renal cell carcinoma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., McFadden, E. T., & Carbone, P. P. (1982) · AMERICAN JOURNAL OF CLINICAL ONCOLOGY · doi:10.1097/00000421-198212000-00014 · Cited by 11,647
Rosenberg, S. A., Lotze, M. T., Muul, L. M., Chang, A. E., Avis, F. P., Leitman, S., Linehan, W. M., Robertson, C. N., Lee, R. E., Rubin, J. T., et al. (1987) · New England Journal of Medicine · doi:10.1056/nejm198704093161501 · Cited by 2,735
Self-citationStructure and expression of a cloned cDNA for human interleukin-2
Taniguchi, T., Matsui, H., Fujita, T., Takaoka, C., Kashima, N., Yoshimoto, R., & Hamuro, J. (1983) · Nature · doi:10.1038/302305a0 · Cited by 1,182
Rosenberg, S. A., Mulé, J. J., Spiess, P. J., Reichert, C. M., & Schwarz, S. L. (1985) · The Journal of experimental medicine · doi:10.1084/jem.161.5.1169 · Cited by 745
Self-citationRosenberg, S. A., Lotze, M. T., Yang, J. C., Topalian, S. L., Chang, A. E., Schwartzentruber, D. J., Aebersold, P., Leitman, S., Linehan, W. M., Seipp, C. A., et al. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.8.622 · Cited by 639
Self-citationKarnofsky Memorial Lecture. The immunotherapy and gene therapy of cancer.
Rosenberg, S. A. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.2.180 · Cited by 390
Self-citationMargolin, K. A., Rayner, A. A., Hawkins, M. J., Atkins, M. B., Dutcher, J. P., Fisher, R. I., Weiss, G. R., Doroshow, J. H., Jaffe, H. S., & Roper, M. (1989) · Journal of Clinical Oncology · doi:10.1200/jco.1989.7.4.486 · Cited by 346
Self-citationHypothyroidism after Treatment with Interleukin-2 and Lymphokine-Activated Killer Cells
Atkins, M. B., Mier, J. W., Parkinson, D. R., Gould, J. A., Berkman, E. M., & Kaplan, M. M. (1988) · New England Journal of Medicine · doi:10.1056/nejm198806163182401 · Cited by 318
Self-citationHormonal therapy and chemotherapy of renal-cell carcinoma.
Harris, D. T. (1983) · PubMed · Cited by 171
Rosenberg, S. A., Lotze, M. T., Muul, L. M., Leitman, S. F., Chang, A. E., Vetto, J. T., Seipp, C. A., & Simpson, C. (1986) · PubMed · Cited by 102
Self-citationBock, S. N., Lee, R. E., Fisher, B., Rubin, J. T., Schwartzentruber, D. J., Wei, J. P., Callender, D. P., Yang, J. C., Lotze, M. T., & Pizzo, P. A. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.1.161 · Cited by 101
Thyroiditis after treatment with interleukin-2 and interferon α-2a
Pichert, G., Jost, L. M., Zöbeli, L., Odermatt, B., Pedia, G., & Stahel, R. A. (1990) · British Journal of Cancer · doi:10.1038/bjc.1990.237 · Cited by 72
Scalzo, S., Gengaro, A., Boccoli, G., Masciulli, R., Giannella, G., Salvo, G., Marolla, P., Carlini, P., Massimini, G., Holdener, E. E., et al. (1990) · European Journal of Cancer and Clinical Oncology · doi:10.1016/0277-5379(90)90275-x · Cited by 61
Pockaj, B. A., Topalian, S. L., Steinberg, S. M., White, D. E., & Rosenberg, S. A. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.1.136 · Cited by 50
Self-citationSauter, N. P., Atkins, M. B., Mier, J. W., & Lechan, R. M. (1992) · The American Journal of Medicine · doi:10.1016/0002-9343(92)90278-j · Cited by 46
Acute Thyroid Dysfunction (Thyroiditis) after Therapy with Interleukin-2
Vassilopoulou‐Sellin, R., Sella, A., Dexeus, F. H., Theriault, R. L., & Pololoff, D. (1992) · Hormone and Metabolic Research · doi:10.1055/s-2007-1003353 · Cited by 44
Jacobs, E. L., Clare-Salzler, M. J., CHOPRA, I. J., & Figlin, R. A. (1991) · Journal of Immunotherapy · doi:10.1097/00002371-199112000-00009 · Cited by 44
HARTMANN, L. C., Urba, W. J., Steis, R., Smith, J. W., VanderMolen, L. A., Creekmore, S. P., Sznol, M., CASCIANO, M. A., ENGLER, N., & LONGO, D. L. (1989) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/81.15.1190 · Cited by 26
Self-citation
Cited by
Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma
Escudier, B., Eisen, T., Stadler, W. M., Szczylik, C., Oudard, S., Siebels, M., Negrier, S., Chevreau, C., Solska, E., Desai, A. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa060655 · Cited by 4,802
Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma
Hudes, G., Carducci, M., Tomczak, P., Dutcher, J., Figlin, R., Kapoor, A., Staroslawska, E., Sosman, J., McDermott, D., Bodrogi, I., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066838 · Cited by 3,647
Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Escudier, B., Porta, C., Schmidinger, M., Algaba, F., Patard, J. J., Khoo, V., Eisen, T., & Horwich, A. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu259 · Cited by 2,251
Motzer, R. J., Bander, N. H., & Nanus, D. M. (1996) · New England Journal of Medicine · doi:10.1056/nejm199609193351207 · Cited by 2,219
Atkins, M. B., Lotze, M. T., Dutcher, J. P., Fisher, R. I., Weiss, G., Margolin, K., Abrams, J., Sznol, M., Parkinson, D., Hawkins, M., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.7.2105 · Cited by 2,048
Self-citation
Metadata
- Authors
- Fyfe, G., Fisher, R. I., Rosenberg, S. A., Sznol, M., Parkinson, D. R., & Louie, A. C.
- Venue
- Journal of Clinical Oncology
- Published
- 1995-03
- Volume
- 13
- Issue
- 3
- Pages
- 688-696
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2123914905
- Cited by
- 1,391
- References
- 18
- FWCI
- 15.90
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.